IN
Item 9 Labs Corp.
INLB · OTC
$0.00 +0.00% (+$0.00)
Market Cap $70.2K
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/B 0.00x
P/S 0.00x
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 102.51%
Rev. growth 63.98%
FCF growth N/A
Profitability
13 /100
Weak Net margin 143.14%
Op. margin 106.01%
FCF margin 35.45%
Quality
3 /100
Poor ROA 28.12%
Asset turnover 0.20x
ROIC 25.60%
Debt
61 /100
Moderate Current ratio 0.09x
Int. coverage -3.86x
Net debt/EBITDA -1.22x
Stability
1 /100
Unstable Rev. volatility 86.24%
EPS volatility 85.31%
Profitable years 0
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o INLB
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Jeffrey I. Rassas
Employees
97
Headquarters
Phoenix
Nadchodzące wydarzenia
02 GRU
Earnings
Upcoming earnings report